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Abstract
Background: In recurrent malignant gliomas (MGs), a high rate of haematological toxicity is observed
with the use of fotemustine at the conventional schedule (100 mg/m2 weekly for 3 consecutive weeks
followed by triweekly administration after a 5-week rest period). Also, the impact of O6-methylguanine-
DNA methyltransferase (MGMT) promoter methylation status on fotemustine activity has never been
explored in the clinical setting.
Methods: 40 patients with recurrent pretreated MG were identified as being treated with fotemustine at
doses ranging from 65 mg/m2 to 100 mg/m2. Patients were classified into 3 groups according to the dose
of fotemustine received, from the lowest dosage received in group A, to the highest in group C. Analysis
of MGMT promoter methylation in tumor tissue was successfully performed in 19 patients.
Results: Overall, 20% of patients responded to treatment, for a disease control rate (DCR, responses
plus stabilizations) of 47.5%. Groups A and B experienced a response rate of 40% and 26.5% respectively,
while the corresponding value for group C was 10%. Out of 19 patients, MGMT promoter was found
methylated in 12 cases among which a DCR of 66.5% was observed. All 7 patients with unmethylated
MGMT promoter were progressive to fotemustine.
Conclusion:  Low-dose fotemustine at 65–75 mg/m2  (induction phase) followed by 75–85 mg/m2
(maintenance phase) has an activity comparable to that of the conventional schedule. By determination of
the MGMT promoter methylation status patients might be identified who are more likely to benefit from
fotemustine chemotherapy.
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Background
Malignant gliomas (MGs) account for approximately 50%
of all malignant primary brain tumors in adults [1].
Standard therapy for newly diagnosed disease includes
surgical resection when feasible, radiotherapy and chem-
otherapy. Particularly, the role of chemotherapy has pro-
gressively become more important ever since a
metanalysis suggested a small but significant increase in
the 1-year survival rate of MG patients treated with adju-
vant chemotherapy [2]. However, despite optimal treat-
ment, median survival ranges from 12 to 15 months for
glioblastoma multiforme (GBM) and from 2 to 5 years for
anaplastic gliomas [3]. Such a dismal prognosis is mainly
to ascribe to the rapid onset of radio- and/or chemo-resist-
ance as well as to the limited therapeutic options available
for MGs recurring after standard treatment.
Fotemustine is an alkylating cytotoxic agent belonging to
the nitrosurea family [4]. Its elevated lipophilic proper-
ties, higher than those of other classical nitrosoureas such
as carmustine (BCNU) and lomustine (CCNU), allow the
drug to better penetrate through the blood-brain barrier
and into malignant cells [5,6]. As single-agent, fotemus-
tine has shown an activity ranging from 15.5% to 26% in
recurrent MGs [7-9]. However, at the conventional sched-
ule of 100 mg/m2 weekly for 3 consecutive weeks fol-
lowed by triweekly administration after a 5-week rest
period, myelosuppression represents a considerable issue.
In fact, in a phase II study by Frenay et al., 23% and 17%
of all patients developed grade 3 and 4 thrombocytopenia
and leukopenia respectively, with severe myelosuppres-
sion being reported in more than 30% of the subpopula-
tion pretreated with chemotherapy [8]. More recently,
even higher rates of myelotoxicity were recorded by Tre-
visan et al. where fotemustine monotherapy led to grade
3 and 4 thrombocytopenia and leukopenia in 55.6% and
50.6% of patients respectively [9]. The frequent develop-
ment of severe haematological toxicity occurring with the
conventional schedule of fotemustine might result into
impairment of treatment activity due to dose omissions
and/or reductions.
Preclinical evidence suggests that the O6-methylguanine-
DNA methyltransferase (MGMT) repair protein is
involved in resistance to alkylating agents including
fotemustine [10-12]. That is because MGMT is implicated
in the removal of DNA alkyl adducts from the O6 position
of guanine, one of the targets of alkylating drugs. Methyl-
ation of the MGMT promoter results in gene inactivation,
thus potentially leading to increased sensitivity to treat-
ment. In GBM, the MGMT promoter methylation has
been proven to be a positive outcome predictor of treat-
ment with the alkylating agent temozolomide [13]. How-
ever, no study has ever related in the clinical setting the
MGMT promoter methylation status to the activity of
fotemustine chemotherapy.
In order to address the importance of the dose of fotemus-
tine in the treatment of recurrent MGs, we conducted an
observational study evaluating the activity and safety of
different doses of fotemustine monotherapy. In patients
with available tissue the MGMT promoter methylation
status was assessed.
Methods
Population and treatment plan
The medical records of the Regina Elena Cancer Institute
in Rome were reviewed in order to identify patients with
histologically proven MG (glioblastoma multiforme, ana-
plastic astrocytoma, anaplastic oligoastrocytoma and ana-
plastic oligodendroglioma) who had been treated with
single-agent fotemustine as second- or third-line chemo-
therapy, regardless of the dose of fotemustine received.
Eligible patients were required to have radiological evi-
dence of tumor recurrence or progression prior to initia-
tion of fotemustine chemotherapy. Moreover, to be
eligible all patients had to have received at least one prior
line of chemotherapy.
Retrospective chart review was approved by the Institu-
tional Review Board of the Regina Elena Cancer Institute.
Fourty patients (table 1) were identified as being treated
with i.v. fotemustine at doses ranging from 65 mg/m2 to
100 mg/m2 weekly for 3 consecutive cycles (induction
phase) followed by a 5-week rest period, after which treat-
ment was resumed with cycles of triweekly fotemustine at
doses ranging from 75 mg/m2 to 100 mg/m2 (mainte-
nance phase). Doses of fotemustine were given at physi-
cian discretion in relation to Karnofsky performance
status (KPS) of each patient. For analysis purposes,
patients were classified into 3 groups according to the
dose of fotemustine received (from the lowest dosage
received in group A, to the highest in group C) (table 2).
Once a certain dosage of fotemustine was adopted, either
in the induction or maintenance phase, it was never esca-
lated in the same patient. In the absence of withdrawal of
the patient or unacceptable toxicity, treatment was contin-
ued until disease progression.
Response and toxicity assessment
Tumor evaluation was performed through brain MRI.
Response to treatment was assessed at baseline, before the
start of maintenance fotemustine and every 3 cycles there-
after or whenever disease progression was clinically sus-
pected. Macdonald criteria were uniformly adopted for
response evaluation [14].
Toxicity was assessed before each fotemustine administra-
tion by medical history, physical examination, hematol-
ogy and biochemistry. Adverse events were graded 1–4
according to NCI-CTCAEv3 version 3.0 [15]. Fotemustine
administration was omitted in case of grade 3–4 neutro-BMC Cancer 2009, 9:101 http://www.biomedcentral.com/1471-2407/9/101
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penia and/or thrombocytopenia, febrile neutropenia and
grade 3–4 non-hematological toxicity except for nausea/
vomiting. At recovery treatment was resumed with a 25%
dose reduction.
Serotonin antagonists were commonly administered for
anti-emetic prophylaxis. Anti-epileptics were adminis-
tered as medically indicated. Glucocorticoids were given
to the lowest dose necessary for neurologic stability and
any modification of steroidal therapy was considered
when evaluating response according the criteria of Mac-
donald et al. [14].
MGMT promoter methylation analysis
Genomic DNA was isolated from one paraffin section of
malignant glioma tissue collected at the time of first diag-
nosis (Ex-Wax DNA Extraction Kit S4530, Chemicon)
(proteinase digestion lasted a maximum of six hours).
DNA was denatured with sodium hydroxide in a volume
of 35 μl and subjected to bisulfite treatment in a volume
of 350 μl (4.4 M sodium bisulfite and 20 mM hydroqui-
none) for five hours at 55°C and then purified. Unmeth-
ylated cytosine, but not its methylated counterpart, is
modified into uracil by the treatment. The methylation-
specific PCR was performed in a two-step approach. The
results were confirmed in an independent experiment,
starting with reisolation of DNA from the tumor. The PCR
products were separated on 4 percent agarose gels.
Statistical Analysis
Descriptive statistics were used to summarize pertinent
study information. The objective response rate was
reported with its 95% confidence interval. The association
between variables was tested by the Pearson Chi-Square
test or Fisher's Exact test. Disease control rate (DCR) was
the sum of partial responses plus stable disease. Progres-
sion-free survival (PFS) and overall survival (OS) were cal-
culated by the Kaplan-Meier product-limit method. PFS
Table 1: Patients characteristics
Characteristic All patients no. = 40
Median age, years (range) 42.1 (26–76)
Median KPS 80 (60–100)
Histotype:
Glioblastoma multiforme 14 (35%)
Anaplastic astrocytoma 11 (27.5%)
Anaplastic oligoastrocytoma 7 (17.5%)
Anaplastic oligodendroglioma 8 (20%)
Prior surgery
Biopsy 8 (20%)
Partial resection 7 (17.5%)
Total resection 25 (62.5%)
Prior radiotherapy 40 (100%)
Prior lines of chemotherapy
1 30 (75%)
2 10 (25%)
Type of prior chemotherapy
TMZ 30 (75%)
PCV – TMZ 10 (25%)
Second surgery 19 (47.5%)
Median time from diagnosis, months (range) 20 (8–173)
Glioblastoma multiforme 10 (8–108)
Anaplastic astrocytoma 28.4 (10–60)
Anaplastic Oligoastrocytoma 35 (9–173)
Anaplastic Oligodendroglioma 25 (11–118)
KPS, Karnofsky Performance Status; no, number; PCV, procarbazine-lomustine-vincristine; TMZ, temozolomide
Table 2: Distribution of patients according to the dose of fotemustine received
Group  Induction dose, mg/m2 (no. pts) Maintenance dose, mg/m2 (no. of pts) All pts no. = 40
A 65 (5) 75 (5) 5
B 75 (15) 75 (10) – 85 (5) 15
C 85 (10) – 100 (10) 75/85 (18) – 100 (2) 20
no., number; pts, patientsBMC Cancer 2009, 9:101 http://www.biomedcentral.com/1471-2407/9/101
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was the time elapsing from the start of fotemustine ther-
apy to the date of objective evidence of disease progres-
sion or death of the patient in the absence of documented
disease progression. OS was estimated from the first day
of treatment with fotemustine to the date of death of the
patient due to any cause. If a patient had not progressed/
died, progression and survival were censored at the time
of the last visit. The log-rank test was used to assess differ-
ences between subgroups. Significance was defined at the
p < 0.05 level [16]. The Hazard risk and the confidence
limits were estimated for each variable using the Cox uni-
variate model and adopting the most suitable prognostic
category as referent group [17]. A multivariate Cox pro-
portional hazard model was also developed using step-
wise regression (forward selection) with predictive
variables which were significant in the univariate analyses.
Enter limit and remove limit were p = 0.10 and p = 0.15
respectively. The SPSS (13.0) statistical program was used
for analysis.
Results
Patients characteristics
The characteristics of the 40 patients are listed in table 1.
Median age was 42.1 years and GBM was the most repre-
sented histotype (35% of cases). Approximately two third
of patients had received total resection as primary surgery
for MG and 47.5% of patients had undergone second sur-
gery at disease recurrence. All patients had been previ-
ously treated with standard curative radiotherapy.
Seventy-five percent of patients had been administered
temozolomide as first-line chemotherapy, while the
remainder had been treated with upfront procarbazine-
lomustine-vincristine (PCV) therapy followed by second-
line temozolomide. All patients completed the induction
phase of fotemustine and received at least one cycle of
fotemustine in the maintenance phase.
Activity
The median number of cycles administered was 6 (range
4–8). Overall activity comprised 8 partial responses (20%;
C.I.95%: 7.6–32.4) and 11 (27.5%) disease stabilizations
for a DCR of 47.5%. Twenty-one patients (52.5%) experi-
enced disease progression. All responding patients had
previously responded to temozolomide chemotherapy
(data not shown).
Progression free survival and overall survival
At a median follow-up of 10 months (range 1–42),
median PFS was 4 months (95% CI 2.0–5.6). The rate of
patients who were free of progression at 6 and 12 months
was 27% and 3.5% respectively.
Median OS was 30 months (95% CI 18.6–42.1). At 24
and 48 months from the start of fotemustine therapy,
87.5% and 57.5% of patients were alive respectively. OS
was significantly higher among responders to fotemustine
as compared to non-responders (60.8% versus 27.8%, p =
0.007) (figure 1).
Activity according to dose, histotype and line of 
chemotherapy
Table 3 shows the activity of fotemustine chemotherapy
according to the adopted dosage and the histotype.
Groups A and B showed a response rate of 40% and
26.5% respectively, whereas patients in group C
responded in 10% of cases. The median number of
fotemustine cycles in groups A and B was 6 (range 6–8),
while the corresponding value for group C was 4 (range
4–6). The cumulative distribution of GBM was 40%,
26.5% and 40% for groups A, B and C, respectively.
Among the 30 patients who received fotemustine as sec-
ond-line treatment, DCR was 46.5%, while a DCR of 50%
was observed in the 10 patients who were administered
fotemustine as third-line therapy (Table 4).
Multivariate analysis
At the multivariate analysis, among the examined varia-
bles (age, histotype, surgery, response to first-line and
fotemustine therapy) activity of fotemustine chemother-
apy (DCR versus progressive disease) was an independent
prognostic factor for both PFS (p < 0.0001) and OS (p =
0.02), whereas the presence of a less aggressive histotype
(anaplastic oligoastrocytoma + anaplastic oligodendrogli-
oma versus others) and activity of first-line chemotherapy
(DCR versus progressive disease) were independent prog-
nostic factors for OS (p = 0.08 and p = 0.005 respectively)
(data not shown).
Overall Survival in relation to response to fotemustine (all  patients, n = 40) Figure 1
Overall Survival in relation to response to fotemus-
tine (all patients, n = 40). Responders = patients achieving 
partial response – Non-responders = patients achieving 
either stable or progressive disease.BMC Cancer 2009, 9:101 http://www.biomedcentral.com/1471-2407/9/101
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Toxicity
Grade 3 and 4 thrombocytopenia and neutropenia
occurred in 8 (20%) and 6 (15%) patients respectively
(table 5). They were only observed in group C patients.
Severe thrombocytopenia and neutropenia led to a 25%
dose reduction in 8 patients in group C.
Besides grade 3 hepatic toxicity and grade 3 emesis occur-
ring in 2 patients in group C, no other severe non-hemath-
ological toxicity were recorded (table 5).
MGMT analysis
The assessment of the MGMT promoter methylation sta-
tus was successfully performed in tumors from 19 individ-
uals (table 6). MGMT promoter was found methylated in
12 patients, among which 3 responses and 5 disease stabi-
lizations were observed (DCR of 66.5%). Progressive dis-
ease was recorded in all 7 patients with unmethylated
MGMT.
Median PFS of patients with methylated MGMT promoter
was 7 months (range 1–12) versus 6 months (range 1–10)
of the unmethylated patients (p = 0.55). Median OS was
45 months (95% CI 14.0–76.5) for MGMT methylated
patients versus 22 months (95% CI 17.1–27.5) for MGMT
unmethylated patients (p = 0.27).
Discussion
Medical treatment of recurrent MG is challenging. The
poor availability of active chemotherapeutic drugs repre-
sents a major limitation in the decision-making process
guiding treatment choice after failure of first-line chemo-
therapy. In addition to this, rapid tumor progression and
low KPS of the patient are other important factors ham-
pering re-treatment with chemotherapy. Against this back-
ground, recommendations for medical treatment of
recurrent pretreated MGs are based almost exclusively on
uncontrolled phase II studies.
In the present analysis, we found that fotemustine mono-
therapy is able to provide a response of 20% for an overall
DCR of 47.5%, which is remarkable since these findings
were observed in a heavily pretreated population (all
patients had received at least one line of chemotherapy
and 25% of patients had received two prior lines). These
activity results are in line with those reported in the liter-
ature with single-agent fotemustine at the conventional
schedule of 100 mg/m2, where a response rate of 15.5%–
26% and a DCR of 50%–76% have been reported [7-9].
However, it should be noted that a less extensively pre-
treated population was included in the oldest studies (0–
26.5% of patients had received previous chemotherapy)
and, more importantly, CT scan instead of MRI was uni-
formly used to assess tumor response [7,8]. On the other
Table 3: Activity of fotemustine in relation to group of dose and histotype
Group A, no. pts (%) (histotype) Group B, no. pts (%) (histotype) Group C, no. pts (%) (histotype)
Partial Response 2 (40%)
(2 AA)
4 (26.5%)
(1 GBM, 3 AOD)
2 (10%)
(1 AA, 1 AOD)
Stable Disease 2 (40%)
(1 GBM, 1 AA)
4 (26.5%)
(1 GBM, 2 AA, 1 AOD)
5 (25%)
(2 GBM, 1 AA, 2 AOA)
Progression 1 (20%)
(1 GBM)
7 (47%)
(2 GBM, 2 AA, 3 AOA)
13 (65%)
(6 GBM, 2 AA, 2 AOA, 3 AOD)
Total pts 5 15 20
Total GBM 2/5 (40%) 4/15 (26.5%) 8/20 (40%)
AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma, AOD, anaplastic oligodendroglioma; GBM, glioblastoma multiforme; no., number; 
pts, patients
Table 4: Activity of fotemustine according to line of chemotherapy and histotype
Activity in 2nd line
no. pts (%) 
(histotype)
Activity in 3rdline
no. pts (%)
(histotype)
Total pts
Partial Response 5 (16.5%)
(1 GBM, 2 AA, 2 AOD)
3 (30%)
(1 AA, 2 AOD)
8
Stable Disease 9 (30%)
(3 GBM, 4 AA, 1 AOA, 1 AOD)
2 (20%)
(1 GBM, 1 AOA)
11
Progression 16 (53.5%)
(7 GBM, 3 AA, 4 AOA, 2 AOD)
5 (50%)
(2 GBM, 1 AA, 1 AOA, 1 AOD)
21
Total pts 30 10 40
AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma, AOD, anaplastic oligodendroglioma; GBM, glioblastoma multiforme; no., number; 
pts, patientsBMC Cancer 2009, 9:101 http://www.biomedcentral.com/1471-2407/9/101
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hand, our PFS at 6 months of 27% compares favorably
with a PFS-6 months of 15% observed in a very recent
report by Trevisan et al. [9]. To this regard, it is reasonable
to argue whether or not this difference in PFS should be
attributed to the lower dose of fotemustine adopted in the
majority of our patients which might have resulted into
better tolerability of treatment. In fact, the population of
the two studies is similar in that both reports include
patients with recurrent MGs pretreated with ≥ 1 line of
chemotherapy; yet, a much higher incidence of severe
myelosuppression was recorded by Trevisan et al. with the
use of a conventional schedule of fotemustine at 100 mg/
m2 [9].
Interestingly, in our study fotemustine monotherapy pro-
duced more enthusiastic results than those reported with
"older" nitrosureas. In a retrospective study, Kappelle et
al. found a response of only 3% with the classical triple
combination PCV in recurrent GBM [18]. More recently,
Rosenthal et al. reported 4% of responses with the use of
BCNU for recurrent MG patients pretreated with temo-
zolomide [19]. Better activity results were obtained in
GBM patients with the combination of BCNU and irinote-
can [20], although polychemotherapy for recurrent MGs
is usually associated with higher toxicity and is bound to
a strong bias of patients selection.
Notably, our analysis also showed the absence of cross-
resistance between fotemustine and temozolomide, since
all responses were observed in temozolomide-pretreated
patients. This observation is worthy of being pointed out
in view of the recent incorporation of temozolomide in
the standard treatment of newly diagnosed glioblastoma
multiforme [21]. Similarly, other authors have reported
an activity of 30% with the use of fotemustine in glioblas-
toma patients pretreated with temozolomide [22]. On the
other hand, the lack of activity observed for fotemustine
in PCV-pretreated patients, suggests the presence of cross-
resistance between fotemustine and other nitrosureas as
hypothesized preclinically [23].
Furthermore, our results showed that both the activity of
first-line therapy and treatment with fotemustine were
positive prognostic factors for OS; these findings confirm
that the use of chemotherapy in recurrent MGs has a pos-
itive impact on patients outcome [24].
The better activity recorded in groups A and B where
fotemustine was given at doses ranging from 65 mg/m2 to
85 mg/m2 is supposedly to ascribe to the absence of severe
myelotoxicity that has allowed the administration of a
higher dose intensity. In fact, at these doses we found no
case of severe thrombocytopenia and/or neutropenia,
whereas the same adverse events were 20% and 15%
respectively in group C, where fotemustine was given at
doses ranging from 75–85 mg/m2 to 100 mg/m2. Impor-
tantly, our data appear to rule out the hypothesis that the
better activity reported for low-dose fotemustine could be
attributed to an imbalanced distribution toward group A
Table 5: Grade 3–4 toxicities per patient (all patients n = 40)
Grade 3–4 haematologic toxicity
Group Neutropenia, no. pts (%) Thrombocytopenia, no. pts (%) Anemia, no. pts (%)
A -- 1  ( 2 . 5 % )
B -- -
C 6 (15%) 8 (20%) 2 (5%)
Grade 3–4 non-haematologic toxicity
Group Hepatic, n. pts (%) Mucositis, n. pts (%) Nausea/vomiting, n. pts (%)
A -- -
B - 1 (2.5%) -
C 2 (5%) - 2 (5%)
Table 6: Activity of fotemustine according to the MGMT promoter methylation status
Methylated MGMT Unmethylated MGMT Total pts
Partial Response 3 (1 GBM, 2 AA) -3
Stable Disease 5 (3 GBM, 2 AA) -5
Progression 4 (2 GBM, 2 AA) 7 (4 GBM, 2 AA, 1 AOA) 11
Total pts 12 7 19
AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma, AOD, anaplastic oligodendroglioma; GBM, glioblastoma multiforme; MGMT, 
methylguanine methyltransferase; pts, patientsBMC Cancer 2009, 9:101 http://www.biomedcentral.com/1471-2407/9/101
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and B of tumors with a worse prognosis such as GBM
(table 3).
Interestingly, fotemustine-induced myelosuppression can
also be lowered by delaying the intervals between each
cycle, as shown recently in two studies exploring fotemus-
tine in combination with either dacarbazine or procar-
bazine for the treatment of recurrent GBM [25,26].
However, the modest response (3%–11%) observed in
these studies showed also that the use of a fotemustine
schedule not including the weekly induction phase might
compromise the activity of fotemustine itself through a
higher rate of early progressions, thus invalidating the
benefits potentially obtainable by the addition of a sec-
ond cytotoxic [25,26]. To this regard, in our study no cases
of early progression were recorded after the induction
phase and all patients received at least six cycles of
fotemustine.
In the 19 patients with tissue available for assessment of
the MGMT promoter methylation status, we found a con-
siderable rate of disease control in patients with methyl-
ated MGMT (8 out of 12, 66.5%) (table 6). More
interestingly, all of the 7 unmethylated patients were
found progressive to fotemustine monotherapy. Despite
the low number of patients analyzed and the heterogene-
ity of patients histotypes, these data suggest that the pres-
ence of MGMT promoter methylation is a crucial
prerequisite for response to fotemustine although it does
not guarantee sensitivity to treatment. On the other hand,
patients with unmethylated MGMT do not appear to ben-
efit at all from fotemustine chemotherapy. However, our
number of patients was too low to observe a significant
difference in terms of efficacy according to MGMT pro-
moter methylation status. For this reason, the role of
MGMT should be further assessed prospectively in a larger
cohort of patients undergoing fotemustine chemother-
apy, possibly re-assessing MGMT status at the time of
tumor recurrence. In fact, a recent study suggested that
changes in the status of MGMT promoter methylation
may occur after primary treatment for newly diagnosed
GBM [27].
Conclusions
This study provides a solid rationale for testing low-dose
fotemustine in the treatment of recurrent MGs. On this
basis, a phase II study investigating fotemustine at the
induction dose of 65 mg/m2 followed by a maintenance
dose of 75 mg/m2 is currently ongoing at 5 different Ital-
ian institutions. Importantly, prospective evaluation of
MGMT methylation is mandatory in patients with tissue
availability.
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